The demand for sensitive and specific assays to determine immune status to varicella can be expected to increase with the anticipated availability of a varicella-zoster virus vaccine More recently, the enzyme-linked immunosorbent assay (ELISA) has been used to determine susceptibility to VZV with good results (6, 8, 10, 12, 14 
The importance of sensitive and specific assays for the determination of immune status to varicella-zoster virus (VZV) has long been recognized. The fluorescent-antibodyto-membrane-antigen (FAMA) test was originally developed because other commonly used tests, such as the complement fixation test, were insensitive, or, in the case of the indirect immunofluorescence assay (IFA) using fixed cells, produced nonspecific reactions when low dilutions were used (13) . A negative FAMA test was subsequently found to correlate well with susceptibility to VZV infection (5) . In addition, detection of FAMA antibody in the spinal fluid was found to correlate with VZV-associated encephalitis (1, 3) . The FAMA test is the standard by which other methods are judged. However, despite improvements (15), it remains somewhat cumbersome.
In the search for a simple but sensitive alternative to the FAMA test, the anticomplement immunofluorescence (ACIF) test has been evaluated. The ACIF test has been used successfully for measuring antibodies to other herpesviruses, since nonspecific fluorescence due to reactions of immunoglobulin with Fc receptors induced on the membranes of herpesvirus-infected cells is avoided. On the whole, correlation between the FAMA and ACIF tests appears to be good (2, 9) , although in one report, ACIF detected only 4 of 43 sera positive by the FAMA test (11) . More recently, the enzyme-linked immunosorbent assay (ELISA) has been used to determine susceptibility to VZV with good results (6, 8, 10, 12, 14 ratories for VZV antibody testing were then tested under code by all three methods. These samples were obtained from patients with neurologic disease in whom a diagnosis of VZV infection was considered. Samples were received from medical facilities throughout Connecticut and the eastern United States. Complete clinical information was not generally available on these patients. In all studies, the FAMA test was considered the reference standard. FAMA procedure. The FAMA test was performed by methods previously described (15). Briefly, seed pools of VZV-infected human foreskin fibroblasts were used to infect two 75-cm2 flasks containing confluent monolayers of human foreskin fibroblasts. When cytopathic effect involved 75% of the monolayer, the cells were dispersed with trypsin and used to infect freshly seeded foreskin fibroblasts in 8 to 10 150-cm2 flasks. When cytopathic effect involved 75% of the monolayers, all cells were trypsinized, washed, and then fixed in a final concentration of 0.075% glutaraldehyde for 60 s at 0°C. Fixation was terminated by the addition of glycine, and the cells were then centrifuged at 600 x g for 10 min at 4°C. The cells were suspended at a concentration of 2 x 106 cells per ml in cold freezing medium (8% dimethyl sulfoxide and 20% fetal calf serum in basal essential medium) and frozen in 0.1-ml aliquots at -70°C until use. Uninfected cells, similarly processed, were used as negative antigen controls. Serum samples were inactivated at 56°C for 30 min and diluted 1:5 in Puck saline. The samples (50-pul aliquots)
were then mixed in 15-ml conical-bottom plastic test tubes with 50 ,lI of VZV-infected or uninfected cells, thawed just before use. The sera and cells were then incubated for 30 min at room temperature. All further reactions and washes were done in these tubes, as previously described (15). After the last washing step, the cell pellets were suspended in (PBS) . The cell pellet from one 75-cm2 flask was suspended in 7 to 10 ml of PBS, and one-fourth volume of trypsinized, washed uninfected MRC-5 cells was added. Monolayers of uninfected MRC-5 cells were processed separately for use as uninfected-cell controls. Approximately 50%o of the cells in VZV-infected cell suspensions were in fact infected. This was done to allow for an additional internal control to avoid nonspecific results. Samples (10 pil) of the appropriate cell suspension were added to individual wells on eight-well toxoplasmosis slides (Bellco Glass, Inc., Vineland, N.J.). The slides were then fixed in acetone for 10 min at 4°C.
For the IFA, as for the FAMA test, all serum samples were screened at a 1:5 dilution and spinal fluids were screened at a 1:2 dilution. A positive control serum was included on each slide. Each sample tested was added to a well containing VZV-infected cells and to a well containing uninfected cells (15 pul of sample in each). The slides were then incubated in a moist chamber for 30 min at 37°C. After incubation, the slides were rinsed in PBS, washed for 10 min with two changes of PBS, rinsed with distilled water, and then air dried. Fluorescein isothiocyanate-conjugated goat anti-human immunoglobulin G (15 pul; Litton Bionetics, Charleston, S.C.) containing Evans blue counterstain was then added, followed by incubation for 30 min at 37°C in a moist chamber. The slides were then washed with PBS as described above, air dried, mounted with buffered glycerol, and examined under a fluorescence microscope. The immunofluorescence observed with acetone-fixed cells was somewhat less intense than that seen with glutaraldehyde-fixed cells, was also confined to the membrane of infected cells, and was absent from uninfected cells with all sera tested.
ELISA procedure. Immunoglobulin (4) . The demand for sensitive and specific assays to determine immune status to VZV will undoubtedly increase in the near future.
The FAMA test remains the "gold standard" for the detection of low levels of VZV antibody. Serum samples can be screened at a 1:2 dilution, as has been done in other studies. However, in some instances a prozone phenomenon has been observed at very low serum dilutions. Furthermore, the consequences of a false-positive titer are much graver in a hospital setting than those of a false-negative titer. Therefore, a screening dilution of 1:5 has been used routinely in the laboratory of one of us (W.A.A.) in this study.
The IFA was criticized in an early study for producing nonspecific results (13) . Starting dilutions of 1:10 have been used to avoid this problem, but this results in a loss of sensitivity (14) . Because of the simplicity of the IFA, which eliminates the laborious washing and cell transfer steps necessary in the FAMA assay, and because VZV is unique among the herpesviruses in that it does not induce Fc receptors on infected cells (7), the IFA was reevaluated in this study. Interestingly, for the 112 serum samples tested, there was 100% agreement between the FAMA test and IFA when the sera were screened at a 1:5 dilution.
Initial reports on the use of ELISA for the determination of VZV immune status have been very promising (6, 8, 10, 12, 14) . In this study, the M.A. Bioproducts ELISA was compared with the FAMA test and IFA, and identical results were obtained with 97 of 101 serum samples tested. In another study, similar results were noted for the M.A. Bioproducts ELISA and the FAMA test (8) . Of the four discrepant samples, two found positive by ELISA and negative by the FAMA test and IFA when tested at a 1:5 dilution were subsequently found to be positive by IFA when a 1:2 dilution was tested. The two remaining samples were positive at low dilution (1:5) by fluorescence and were equivocal to negative by ELISA; one of these samples was found to have a high background reading. It is not known which test correlates best with immunity in these or similar patients. In general, there is complete agreement between FAMA titers of greater than 2 and protection from chicken pox (15).
In addition to determination of immune status, the FAMA test has been used to detect VZV antibody in spinal fluid and thus establish a diagnosis of VZV-associated neurologic disease. To our knowledge, the present study is the first to examine a commercial ELISA or an IFA for this use. Of 31 spinal fluid samples tested, there was 96.8% correlation between the FAMA test and IFA. The M.A. Bioproducts ELISA has been standardized, and criteria for positivity have been established for serum but not for spinal fluid. When these criteria were applied to CSF, 3 of 11 FAMApositive samples were negative by ELISA, for an overall 90.3% correlation between the two tests. In this study, all FAMA-positive samples had ELISA values of 0.08 or greater, whereas all FAMA-negative samples had ELISA values of 0.04 or less. Due to fewer nonspecific reactions encountered with CSF samples than with sera, it may be reasonable to accept a lower value as the positive cutoff. However, additional specimens should be tested in this range by ELISA and the FAMA test and the data preferably should be correlated with clinical information to determine whether this alternative cutoff is appropriate.
In summary, agreement between the three methods, the FAMA test, IFA, and ELISA, for detection of VZV antibody in serum samples was excellent. The simple IFA appears to be an acceptable alternative to the FAMA test. Prepared slides can be kept at -20°C until use, and even a single serum sample can be tested rapidly. The ELISA is available commercially and, because of its objective endpoints and automation, is particularly suitable for screening large numbers of samples for immunity to VZV; it can also be used to detect recent infection (12) . The correlation between the FAMA test, IFA, and ELISA for detection of VZV antibody in spinal fluid was also excellent, but the importance of establishing a positive ELISA cutoff value for CSF was apparent. This information should prove useful in the evaluation of VZV-associated neurologic diseases.
